Coherus BioSciences

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Coherus BioSciences targets profitability in 2024 with strong product focus

Coherus BioSciences is strategically positioned to achieve profitability in 2024 through revenue growth and cost control. The company's strong product portfolio and focus on user-friendly solutions provide a competitive edge. Challenges include competition and regulatory approvals, while opportunities exist in expanding product approvals and optimizing expenses.

Coherus BioSciences reports robust Q1 results and eyes market expansion

Coherus BioSciences showcased strong financial performance, product advancements, and strategic initiatives during their Q1 2023 Earnings Call, positioning them for future growth.
While facing challenges such as potential competition and pricing uncertainties, the company's strengths in product diversity, patient engagement, and commercial readiness offer a solid foundation for success.
By capitalizing on opportunities like FDA approvals, therapy combinations, and market share goals, Coherus can navigate challenges and drive innovation in the biopharmaceutical market.

Coherus BioSciences posts robust Q2 earnings, eyes market expansion

Coherus BioSciences reported strong Q2 2023 performance with net product revenues of $58.5 million.
The company aims to achieve cash flow positivity in 2024 through expense management and revenue growth.
Focus on offering low-cost alternatives like CIMERLI and expanding market share for key products.
Plans to leverage the successful launches of UDENYCA and Toripalimab for future growth opportunities.

Coherus BioSciences reports strong Q3 revenue growth and profitability focus

Coherus BioSciences showed strong revenue growth and expense management focus for profitability.
Key products like CIMERLI and UDENYCA drove revenue growth in Q3 2023.
Adjusting R&D expenses to align with revenue and focusing on profitability until mid-2024.
Analysts raised questions on pricing dynamics, profitability goals, and pipeline development plans.

Coherus BioSciences reports strong Q4 results and focuses on growth

Coherus BioSciences showcased strong Q4 results, focusing on efficiency and growth in 2024.
The company achieved FDA approvals for key products, with UDENYCA sales showing growth and LOQTORZI gaining traction.
Financials highlighted cost reductions and pipeline progress, with a cautious approach to revenue projections.
Emphasis on controlling expenses, reducing debt, and driving revenues higher while investing in key products.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– Commercial launch of CIMERLI™ planned for early October 2022 – – PDUFA date for toripalimab BLA is December 23, 2022 – – Commercial preparation underway for planned July 2023 launch of YUSIMRY™ – – UDENYCA® delivers 2 nd quarter 2022 net sales of $60.1 million – – Conference call today at 5 p.m. ET –

Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update

The consensus price target hints at an 84.6% upside potential for Coherus BioSciences (CHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict an 85% Upside in Coherus BioSciences (CHRS): Here's What You Should Know

- CIMERLI™ is Coherus' third FDA-approved product and the first of four new product launches planned by the end of 2023 -

FDA Approves Coherus' CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after market close on Thursday, August 4th, 2022. Starting at 5 p.m. ET, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022

Coherus, an established biosim developer, partnered with a Chinese company to bring a PD-1 inhibitor to the US. However, the trial was entirely done in China.

Coherus: Will Its Chinese Gambit Fail?

- Dr. O'Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute's efforts to advance cancer immunotherapies -

Coherus BioSciences Appoints Dr. Jill O'Donnell-Tormey to its Board of Directors

REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May.

Coherus BioSciences Management to Present at Upcoming Investor Conferences

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants McDavid Stilwell - CFO Denny Lanfear - President, CEO, and Chairman Paul Reider - CCO Theresa LaVallee - CDO Conference Call Participants Balaji Prasad - Barclays Jason Gerberry - Bank of America Georgi Yordanov - Cowen and Company Operator Good day, and thank you for standing by. Welcome to the Coherus Biosciences Inc. First Quarter 2022 Earnings Conference Call.

Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q1 2022 Earnings Call Transcript

– CIMERLI ™ BLA review progressing toward August 2022 action date – – Toripalimab BLA resubmission expected by mid-summer – – UDENYCA® delivers 1 st quarter 2022 net sales of $60.1 million – – 2022 R&D and SG&A expense guidance reduced by $20 million – – Conference call today at 4:30 p.m. ET –

Coherus BioSciences Reports First Quarter 2022 Results

- Biotechnology Chief Financial Officer and highly regarded former healthcare investment banker brings decades of industry experience to Coherus' immuno-oncology strategy execution -

Coherus BioSciences Appoints Charlie Newton to Board of Directors

The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ: CHRS) toripalimab application for advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). NPC is a rare tumor of the head and neck.

FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer

REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (Nasdaq: CHRS), please note in the Conference Call Information, the start time should be 4:30 p.m. ET, not 5 p.m. ET as previously stated. The corrected release follows:

CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022

REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2022 financial results will be released after the close of the United States financial markets on Thursday, May 5th, 2022. Starting at 4:30 p.m. ET, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Coherus BioSciences (CHRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Alnylam Pharmaceuticals

Aptinyx Inc

Bristol-Myers

Blueprint Medicines

Hutchison China MediTech Ltd.

Tarsus Pharmaceuticals

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belonging to the sector seeing some of these make-or-break catalysts.

7 Biotech Stocks to Buy With Key Catalysts for April

— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth –

Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event

REDWOOD CITY, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City. Coherus executives and scientists will provide updates on the preparation for multiple potential new product launches anticipated over the next 15 months as well as the Company's transformational entry into immuno-oncology with PD-1 inhibitor toripalimab and innovative PD-1 combination candidates.

Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event

- Dr. Dias is a biotech and pharma industry executive with more than 20 years of global experience launching oncology products - - Dr. Dias is a biotech and pharma industry executive with more than 20 years of global experience launching oncology products -

Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer

REDWOOD CITY, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the following investor conferences in March.

Coherus Management to Present at Upcoming Investor Conferences

Coherus BioSciences Inc's (NASDAQ: CHRS) Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates of $85.81 million. The decline was primarily due to a decrease in the number of units of Udenyca sold and a reduction in net realized price due to increased competition and COVID-19 impacts.

Coherus BioSciences' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices

Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q4 2021 Results - Earnings Call Transcript

– YUSIMRY™ (adalimumab-aqvh), Coherus' second product, approved by FDA on December 17, 2021 – – BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI™ (ranibizumab-ranq) – – New FDA filings expected in 2022 for UDENYCA® on-body injector and additional toripalimab indications – – UDENYCA® delivered net sales of $73 million in 4Q 2021; $327 million in FY 2021 – – Conference call and webcast today at 5:00 p.m. ET –

Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results

REDWOOD CITY, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Paul Reider has been named Chief Commercial Officer. Mr. Reider previously held the position of Executive Vice President of Commercial Operations and Market Access.

Coherus Names Paul Reider Chief Commercial Officer

REDWOOD CITY, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be released after market close on Thursday, February 17, 2022. Starting at 5 p.m. ET, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022

Jim Healy, Director since 2014, steps down from the Coherus board Jim Healy, Director since 2014, steps down from the Coherus board

News for Coherus BioSciences Stock (CHRS)